Entropy Presents IV Psilocin Platform Designed to Solve Oral Psilocybin Scaling Issues
Entropy Neurodynamics outlines TRP-8803 precision psychedelic platform at Australian Microcap Investment Conference
In its May 2026 investor presentation, Entropy Neurodynamics outlined its clinical-stage development of IV-infused psilocin therapies designed to address the limitations of oral psilocybin. Managing Director and CEO Jason Carroll presented the company’s strategic thesis at the 15th Annual Australian Microcap Investment Conference in Sydney, highlighting the lead programme TRP-8803 and recent breakthrough clinical results in treatment-resistant irritable bowel syndrome (IBS). The presentation came shortly after the company reported a 75% response rate in IBS patients at Digestive Disease Week Congress 2026, representing what researchers from Massachusetts General Hospital and Columbia University described as the strongest clinical signal ever reported in IBS drug development.
Management detailed the company’s position with a market capitalisation of AU$57.1 million (at $0.035 per share), AU$6.5 million cash at bank as at 31 March 2026, 1.632 billion shares on issue, and nil debt. The top 10 shareholders hold 40.8% of the register, with co-founder Dr William James Garner holding 13.6%, and management and board holding meaningful stakes including CEO Jason Carroll at 3.8%, Chairman Herwig Janssen at 2.3%, and Non-Executive Director Dr Daniel Tillett at 4.1%.
When big ASX news breaks, our subscribers know first
What is IV-infused psilocin and why does it matter for investors?
Psilocin is the active metabolite of psilocybin, meaning it is the compound that produces therapeutic effects once psilocybin is absorbed and processed by the body. The presentation detailed the clinical drawbacks of oral psilocybin that TRP-8803 is designed to overcome. Oral psilocybin delivers variable onset times of 1-3 hours, uncontrolled drug exposure once swallowed, and long treatment sessions lasting 8-10 hours, creating an inefficient model with high staffing burden and limited time spent in the therapeutic zone.
TRP-8803’s intravenous delivery addresses these limitations through rapid onset of approximately 15 minutes, precision control of blood levels within a target therapeutic zone, short treatment duration of 1-2 hours, and the ability to reverse the intervention in emergency situations. The presentation positioned these advantages as creating a commercially scalable model that reduces staffing requirements and operational burden compared to oral psilocybin protocols. The shorter treatment window allows clinics to treat more patients per day while maintaining safety oversight, addressing a key commercial constraint facing oral psilocybin developers post-approval.
| Parameter | IV-Infused Psilocin (TRP-8803) | Oral Psilocybin |
|---|---|---|
| Treatment Duration | 1-2 hours | 8-10 hours |
| Onset Time | ~15 minutes | 1-3 hours (variable) |
| Blood Level Control | Precision targeting | Highly variable |
| Emergency Reversibility | Quickly reversible | Not reversible |
| Commercial Scalability | Yes | Uncertain |
| IP Positioning | Strong (7 patent families) | Weak |
The company’s Phase I clinical data demonstrated that TRP-8803 achieves consistent blood levels within the target therapeutic zone across diverse patient cohorts, eliminating the need for weight-based dosing and removing significant inter-patient variability. Management confirmed the establishment of dosing intensity of 9-10 within 15 minutes across target therapeutic dose cohorts, validating the platform’s ability to deliver predictable pharmacokinetic profiles.
75% response rate in treatment-resistant IBS represents strongest clinical signal in drug class
The presentation highlighted results from the Phase 2a TRP-8802 (oral psilocybin) trial in IBS, which were presented at Digestive Disease Week Congress 2026 by researchers from Massachusetts General Hospital and Columbia University. The 75% response rate was achieved in treatment-resistant patients, a population where existing approved therapies deliver response rates ranging from 17-44%. Management positioned this as validation of the therapeutic mechanism before transitioning to the TRP-8803 platform.
Strongest Clinical Signal in IBS Drug Development
The 75% response rate in treatment-resistant IBS patients represents the strongest clinical signal ever reported in IBS drug development, achieved in the hardest-to-treat patient population where current available therapies are unable to deliver consistent patient benefit.
Response rates varied by IBS subtype, with 100% of IBS-C (constipation-predominant) patients responding, 80% of IBS-M (mixed-type) patients, and 50% of IBS-D (diarrhoea-predominant) patients. The presentation noted that positive clinical outcomes were linked to improvements in psychological insight and flexibility, supporting the gut-brain axis mechanism of action hypothesis and indicating the therapy targets root-cause neurobiological pathways rather than masking symptoms.
The IBS market represents 10.4 million patients in the US spending over US$60 billion annually on treatments. Management outlined that Entropy’s total addressable market across fibromyalgia (FM), IBS, and binge eating disorder (BED) represents US$72 billion, equivalent in size to the combined major depressive disorder (MDD), treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), generalised anxiety disorder (GAD), and obsessive-compulsive disorder (OCD) markets.
Dual pathway opportunity in psychiatry and gastroenterology
The presentation outlined two distinct care models for TRP-8803 deployment. The psychiatry pathway addresses treatment-resistant depression (TRD), PTSD, GAD, and BED through psychotherapy integration, requiring psychiatrist oversight, therapy preparation, guided dosing sessions lasting 2-3 hours, and post-treatment integration therapy focused on emotional processing. The gastroenterology pathway targets IBS-C and IBS-M through infusion-based neuromodulation in standard GI infusion suites, requiring gastroenterologist oversight, medical screening, IV infusion sessions lasting 1-2 hours, and post-treatment GI follow-up for symptom support.
Management positioned the gastroenterology pathway as potentially offering simpler regulatory and commercial entry compared to psychiatric applications, which require Risk Evaluation and Mitigation Strategy (REMS) protocols and suicidality monitoring. The GI pathway uses standard safety oversight familiar to gastroenterologists, expanding the addressable prescriber base beyond psychiatrists. This dual pathway approach creates multiple shots on goal for the platform while addressing different regulatory and reimbursement environments.
Regulatory tailwinds and M&A activity create strategic window
The presentation referenced the US Executive Order accelerating access to psychedelic medicines, which establishes expedited FDA review pathways, adaptive trial designs, and accelerated approval mechanisms. Management outlined that the order directs reimbursement evaluation by the Centers for Medicare & Medicaid Services (CMS) and the Department of Veterans Affairs (VA), with federal coordination across the Department of Health and Human Services (HHS), VA, Department of Defense (DoD), National Institutes of Health (NIH), and Substance Abuse and Mental Health Services Administration (SAMHSA).
Management highlighted two recent M&A transactions validating sector-level interest from major pharmaceutical companies. AbbVie’s acquisition of Gilgamesh Pharma’s bretisilocin (a Phase 2a tryptamine with rapid-acting IV bolus delivery validated in a single 40-patient MDD study) and Otsuka’s acquisition of Transcend Therapeutics’ methylone (an MDMA analogue for PTSD, depression, and anxiety) represented combined transaction values of US$2.42 billion based on early-stage validation. The presentation positioned TRP-8803 as a mechanism-validated precision platform with EEG-guided dosing and predictive algorithms, making it an ideal acquisition target.
The presentation argued that TRP-8803 addresses the scaling challenge facing oral psilocybin post-approval. Management stated that oral psilocybin faces a 2-3 year scaling challenge due to long treatment durations and staffing requirements, creating a strategic window for precision-controlled alternatives. The company’s EEG-guided data, predictive algorithms, and reproducible pharmacokinetic profiles position TRP-8803 as what management described as the inevitable successor to oral psilocybin.
The next major ASX story will hit our subscribers first
Upcoming catalysts and development timeline
Management outlined multiple near-term inflection points across clinical progress, manufacturing readiness, and platform development:
- Cohort 1 clinical readout expected Q3 2026
- Full clinical results anticipated Q4 2026
- Announcement and initiation of 60-patient study
- Interim analysis from expanded study targeted Q1 2027
- Phase 2/3 supply agreement targeted Q3 2026
- Scale-up manufacturing runs and stability testing expected Q1 2027
- Integration of EEG datasets planned Q4 2026
- Entropy biomarker validation targeted Q1 2027
The company has filed seven patent families across major global pharmaceutical markets protecting manufacturing, formulation, dosing, and treatment methods. These families cover improved methods for the use of psychedelics (priority date 15 March 2021), treatment of binge eating disorder (priority date 8 June 2022), psilocin crystalline forms (priority date 12 September 2022), methods of treating fibromyalgia (priority date 12 September 2022), treatment of gut-brain interaction disorders (priority date 3 January 2024), EEG-guided dosing (priority date 12 April 2024), and optimised dosage regimen (filing date 13 August 2025).
The presentation positioned the company ahead of multiple clinical catalysts while maintaining insider alignment, with the top 20 shareholders holding 50.0% of the register and 80.1% held by the top 100 shareholders. Management emphasised that the breakthrough IBS results derisk the TRP-8803 development pathway and strengthen the company’s position for partnering discussions, larger trials, and potential grant funding opportunities within a clear US-focused development pathway.
Ready to Explore Entropy Neurodynamics’ TRP-8803 Platform in Detail?
Entropy Neurodynamics has reported a 75% response rate in treatment-resistant IBS patients, representing what researchers describe as the strongest clinical signal ever achieved in this drug class. The company’s IV-infused psilocin platform addresses the commercial scalability challenges facing oral psilocybin through precision dosing, 1-2 hour treatment windows, and proven pharmacokinetic control.
With multiple Phase 2 readouts expected in Q3-Q4 2026 and a dual pathway strategy spanning gastroenterology and psychiatry, TRP-8803 is positioned at the intersection of breakthrough clinical data and regulatory tailwinds. Visit the Entropy Neurodynamics investor centre to access the full presentation materials, clinical data, and development timeline.